In addition, INDO intercalated in the LDH matrix can be used both as a component and as a coadjuvant of the chemotherapy protocols for triple-negative breast cancer, estrogen receptor-positive breast cancer, gastric cancer with ascitic fluid formation, and diffuse-type gastric cancer, preferable to the use of unmanaged INDO. Here, IDO1 is linked to triple-negative breast carcinoma.